Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071128 | 1.00 | REN (0.33) | RENCTSSEPHX2ALDH1A1GAA | |
| SCHEMBL1071581 | 0.99 | REN (0.34) | RENCTSSEPHX2ALDH1A1GAA | |
| SCHEMBL1069435 | 0.99 | REN (0.34) | RENCTSSEPHX2ALDH1A1GAA | |
| SCHEMBL12963648 | 0.99 | REN (0.34) | RENCTSSEPHX2ALDH1A1GAA | |
| SCHEMBL1072452 | 0.94 | GAA (0.33) | RENCTSSEPHX2ALDH1A1GAA | |
| SCHEMBL20310044 | 0.94 | GAA (0.33) | RENCTSSEPHX2ALDH1A1GAA | |
| SCHEMBL12963557 | 0.93 | GAA (0.35) | RENCTSSEPHX2ALDH1A1GAA | |
| SCHEMBL1070033 | 0.93 | GAA (0.35) | RENCTSSEPHX2ALDH1A1GAA | |
| SCHEMBL8008225 | 0.93 | GAA (0.35) | RENCTSSEPHX2ALDH1A1GAA | |
| SCHEMBL3311882 | 0.93 | GAA (0.35) | RENCTSSEPHX2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | RRP1B, ZC3HAV1, RNASE1 | REN 558/4885CTSS 63/4885EPHX2 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.